Drug recall · June 26, 2019
Robafen DM recall
Why: CGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Robafen DM, Generic for Robitussin DM, In each teaspoonful (5mL): Dextromethorphan HBr, USP 10mg,/Guaifenesin, USP 100mg, 118mL (4oz) bottle, Manufactured for Preferred Pharmaceuticals, Inc., Anaheim, CA 92807 by Major Pharmaceuticals, Livonia, MI 48152, NDC 68788-0841-01
- Lots / codes
Lot: J0218L, Batch: 10021812, Exp. 02/2020; Lot: L2718D, Batch numbers from consecutively from L2718D001 to L2718D096, Exp. 07/2020
- Quantity
- 192 4 oz bottles
- Company
- Preferred Pharmaceuticals, Inc, Anaheim, CA
- Distribution
- Distribution was made to CA and FL.
- Initiated
- June 10, 2019 · Voluntary: Firm initiated
- Classified
- June 20, 2019
- Reported
- June 26, 2019
- Ended
- April 3, 2023
- How notified
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Guaifenesin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.